PTLF (Petlife Pharmaceuticals) Change In Receivables: $0.00 Mil (TTM As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Petlife Pharmaceuticals Change In Receivables?

Petlife Pharmaceuticals PTLF Change In Receivables is $0.00 Mil as of Feb. 2018.

Petlife Pharmaceuticals's change in receivables for the quarter that ended in Feb. 2018 was $0.00 Mil. It means Petlife Pharmaceuticals's Accounts Receivable stayed the same from Nov. 2017 to Feb. 2018 .

Petlife Pharmaceuticals's change in receivables for the fiscal year that ended in Aug. 2017 was $0.00 Mil. It means Petlife Pharmaceuticals's Accounts Receivable stayed the same from Aug. 2016 to Aug. 2017 .

Petlife Pharmaceuticals's Accounts Receivable for the quarter that ended in Feb. 2018 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Petlife Pharmaceuticals's liquidation value for the three months ended in Feb. 2018 was $-1.97 Mil.

Petlife Pharmaceuticals  (OTCPK:PTLF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Petlife Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Feb. 2018 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Petlife Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Petlife Pharmaceuticals's liquidation value for the quarter that ended in Feb. 2018 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.008-1.981+0.75 * 0+0.5 * 0
=-1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Change In Receivables Related Terms

Petlife Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Change In Receivables Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Petlife Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Petlife Pharmaceuticals (PTLF) has a Change In Receivables of $0.00 Mil as of Feb. 2018. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' Change In Receivables too high?
Petlife Pharmaceuticals' current Change In Receivables is $0.00 Mil.
How does Petlife Pharmaceuticals' Change In Receivables compare to PCYN and YBAO?
Petlife Pharmaceuticals' Change In Receivables of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Petlife Pharmaceuticals and its competitors. Petlife Pharmaceuticals's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Change In Receivables is $0.00 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.